Show Summary Details
Page of

Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial 

Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial
Chapter:
Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial
Author(s):

Mary A. Bailey

DOI:
10.1093/med/9780199377527.003.0016
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 October 2019

This chapter provides a summary of a landmark study in multiple sclerosis. Is oral BG-12 safe and efficacious for treating relapsing-remitting multiple sclerosis compared to placebo? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. In patients with relapsing-remitting multiple sclerosis, oral BG-12 was shown to be an effective disease-modifying therapy compared to placebo. This finding gives physicians and patients more options for MS treatments than the well-known, established injectable therapies. The chapter briefly reviews other relevant studies and information.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.